They emphasized that CXCR6 plays an important role in boosting the effectiveness of programmed cell death protein 1 (anti-PD-1) therapy and suggested that the elevated expression of this receptor is driven by factors within the tumor tissue itself rather than by chemotactic signal [124]. This evidence concerns the gene CXCR6 and neoplasm.